NEWS
- Molecular Glue-Antibody Conjugates (MACs)
- FDA Approved Antibody-Drug Conjugates (ADCs) By 2025
- FDA Approval of Semaglutide for MASH - Other Promisiong Pipelines Ahead
- Key Advances in Breast Cancer Treatment: First Half of 2025
- BMS-986238: A New Macrocyclic Peptide-Based PD-L1 Inhibitor
- Peptide Therapeutics: Current Status And Future Directions
- Camptothecin & Its Derivatives for Cancer Therapy
- Peptide-Drug Conjugates (PDCs): Development Status & Research Progress
- FDA Approves First NASH Drug & Other Pipelines in Clinical Trials
- Lumisight (pegulicianine) Gains FDA Approval to Detect Residual Cancer